'Cancer Rates and Risks' Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md--The National Cancer Institute has released the latest edition of Cancer Rates and Risks, a 205-page reference book with cancer statistics and brief chapters by NCI experts, written in lay language, on known cancer risk factors. Single copies are available free through the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

BETHESDA, Md--The National Cancer Institute has released the latest edition of Cancer Rates and Risks, a 205-page reference book with cancer statistics and brief chapters by NCI experts, written in lay language, on known cancer risk factors. Single copies are available free through the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Articles in this issue
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
AIDS Funding Increased for Fiscal '97
'Cancer Rates and Risks' Available
New Breast Cancer Patient Resource Is Available
Short-Term Metronidazole not Linked to Cancer
Various Capitation Models Are Available for Oncology Networks
NCI Urges full Disclosure of Cigarette Contents
Antifungal Resistance on the Increase
Fentanyl Patch Useful Alternative in Cancer Pain Patients
Analysis of Microvessel Density Predicts Extraprostatic Spread
Late Infection With Cytomegalovirus a Serious Problem in Bone Marrow Transplant Patients
FDA Panel Cancels HIV Drug Meeting
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
Foundation Supports Legislation Backing Cancer Treatment Coverage
FDA Approves Xillix LIFE-Lung System

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.